LONDON: PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) noted that its founded entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate was led by General Atlantic, a leading global growth investor,…